JP2004525950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525950A5 JP2004525950A5 JP2002579013A JP2002579013A JP2004525950A5 JP 2004525950 A5 JP2004525950 A5 JP 2004525950A5 JP 2002579013 A JP2002579013 A JP 2002579013A JP 2002579013 A JP2002579013 A JP 2002579013A JP 2004525950 A5 JP2004525950 A5 JP 2004525950A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rapamycin
- tumor
- use according
- mtor inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 18
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 18
- 229960002930 sirolimus Drugs 0.000 claims 18
- 229940124302 mTOR inhibitor Drugs 0.000 claims 10
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 10
- 230000000340 anti-metabolite Effects 0.000 claims 9
- 229940100197 antimetabolite Drugs 0.000 claims 9
- 239000002256 antimetabolite Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- HKVAMNSJSFKALM-CPXURSODSA-N everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C\C=C\C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-CPXURSODSA-N 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000028830 lung neuroendocrine neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28238501P | 2001-04-06 | 2001-04-06 | |
| US28238801P | 2001-04-06 | 2001-04-06 | |
| PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525950A JP2004525950A (ja) | 2004-08-26 |
| JP2004525950A5 true JP2004525950A5 (https=) | 2005-12-22 |
Family
ID=26961412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002579013A Pending JP2004525950A (ja) | 2001-04-06 | 2002-04-05 | ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1385551B1 (https=) |
| JP (1) | JP2004525950A (https=) |
| KR (1) | KR100862178B1 (https=) |
| CN (1) | CN1309421C (https=) |
| AT (1) | ATE406892T1 (https=) |
| AU (1) | AU2007242958A1 (https=) |
| BR (1) | BR0208627A (https=) |
| CA (1) | CA2442849A1 (https=) |
| DE (1) | DE60228699D1 (https=) |
| EA (1) | EA010184B1 (https=) |
| ES (1) | ES2312568T3 (https=) |
| HU (1) | HUP0304093A3 (https=) |
| IL (1) | IL157898A0 (https=) |
| MX (1) | MXPA03009092A (https=) |
| NO (1) | NO20034433L (https=) |
| NZ (1) | NZ540047A (https=) |
| PL (1) | PL363991A1 (https=) |
| PT (1) | PT1385551E (https=) |
| SG (1) | SG152906A1 (https=) |
| SI (1) | SI1385551T1 (https=) |
| WO (1) | WO2002080975A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| MX368013B (es) | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| JP2007525507A (ja) * | 2004-02-26 | 2007-09-06 | ザ ペン ステイト リサーチ ファンデーション | オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法 |
| WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| WO2007059106A2 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of mntor inhibitor to treat patients with cancer |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| NO20220050A1 (no) * | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| WO2007080124A1 (en) * | 2006-01-12 | 2007-07-19 | Novartis Ag | Combination of mtor inhibitor and antipolate compound |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| EP1996193A2 (en) | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| JP5919593B2 (ja) * | 2006-10-11 | 2016-05-18 | フージョン アンティボディーズ リミテッド | 併用療法 |
| JP2010509400A (ja) | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
| JPWO2008088088A1 (ja) | 2007-01-19 | 2010-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 膵癌治療用組成物 |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| CA2278056C (en) * | 1997-01-24 | 2006-12-12 | Norsk Hydro Asa | Gemcitabine derivatives |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525950A5 (https=) | ||
| JPWO2023190748A5 (https=) | ||
| RU2019101632A (ru) | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента | |
| JP2024526145A5 (https=) | ||
| WO2004071436A3 (en) | The use of gcc ligands | |
| JP2008524225A5 (https=) | ||
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| WO2005013800A3 (en) | Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity | |
| RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
| IL159859A (en) | Antineoplastic combinations | |
| TW200407326A (en) | Pyrimido compounds having antiproliferative activity | |
| Monga et al. | Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions: DK MONGA AND MJ O’CONNELL | |
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| MX2009006779A (es) | Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana. | |
| NZ621449A (en) | Treatment with anti-vegf antibodies | |
| JP2006524246A5 (https=) | ||
| JP2005511597A5 (https=) | ||
| JP2004532883A5 (https=) | ||
| FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
| WO2006027693A3 (en) | Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis | |
| JP2023517671A5 (https=) | ||
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| Mukaida et al. | Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer | |
| RU2007115511A (ru) | Способ комбинированного лечения местнораспространенного немелкоклеточного рака легкого | |
| RU2006122136A (ru) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |